NCT00832559View on ClinicalTrials.gov

A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 27, 2009

Primary Completion Date

July 28, 2011

Study Completion Date

July 28, 2011

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

CVA21

1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.

Trial Locations (3)

2010

St Vincents Hospital, Darlinghurst

2310

Calvary Mater Newcastle Hospital, Newcastle

3168

Monash Medical Centre, Clayton

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT00832559 - A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06) | Biotech Hunter | Biotech Hunter